Physician profile
Ryan B West
NPI 1679736037
$2,991.66
in general payments reported to CMS, 2019-2025
29 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $431 · 2021: $436 · 2022: $333 · 2023: $500 · 2024: $589 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $846.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $451.46 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $222.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.48 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $195.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $193.25 | 2019-2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $127.15 | 2020-2023 | |
| Pfizer INC. | $112.12 | 2019-2022 | |
| Exact Sciences Corporation | $100.55 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $81.41 | 2019-2020 | |
| Esperion Therapeutics, INC. | $71.12 | 2020-2025 | Nexletol |
| Abbvie INC. | $63.38 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $45.35 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Shire North American Group INC | $30.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.44 | 2023 | Austedo Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $23.57 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $21.73 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $20.94 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.48 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $20.26 | 2025 | Rexulti |
| Lundbeck LLC | $18.06 | 2025 | Rexulti |
| Minerva Surgical, INC | $14.99 | 2019 | |
| Amgen INC. | $14.55 | 2025 | Evenity |
| Currax Pharmaceuticals LLC | $14.06 | 2025 | Contrave |
| Vertical Pharmaceuticals, LLC | $13.75 | 2024 | Relexxii |
| Supernus Pharmaceuticals, INC. | $12.93 | 2023 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2020 | |
| Amarin Pharma, INC. | $11.90 | 2019 | |
| Corium, LLC | $11.42 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.